Payments to Stanford under license agreement for annual license fees and patent expense reimbursement
| Officer | Age | 2025 pay | Source |
|---|---|---|---|
|
William P. Quinn
Also a director
President, Chief Executive Officer, Chief Financial Officer, Secretary and Director
|
55 | $4,558,368 | |
|
Grant Yonehiro
Chief Operating Officer and Chief Business Officer
|
62 | $4,007,443 | |
|
Sheila Gujrathi
Also a director
Chief Strategy Officer
Title from the Form 8-K dated Oct 23, 2026
|
Not stated | Not reported | |
|
Sarah Nemec
Senior VP, Finance and PAO
Title from the Form 4 dated Sep 16, 2026
|
Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Oct 23, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Brian O’Callaghan
Board chair
|
56 |
2021
5 years
|
Independent |
Compensation Committee · Chair
|
Indaptus Therapeutics, Inc. | $448,937 | |
|
William P. Quinn
CEO, Executive officer
|
55 |
2024
2 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Jakob Dupont, M.D.
|
61 |
2024
2 years
|
Not independent | None stated | Pyxis Oncology, Inc., Imugene Limited | $191,841 | |
|
Kathleen LaPorte
|
64 |
2020
6 years
|
Independent |
Audit Committee · Chair
|
89bio, CERo Therapeutics Holdings, Inc., Q32 Bio, Precipio Diagnostics | $600,249 | |
|
Nicole Onetto, M.D.
|
73 |
2021
5 years
|
Independent |
Nominating and Corporate Governance Committee
|
Basilea Pharmaceutica AG | $310,700 | |
|
Laura Berner
|
51 |
2022
4 years
|
Independent |
Nominating and Corporate Governance Committee · Chair
|
None stated | $173,672 | |
|
Sheila Gujrathi
Joined Oct 23, 2026
|
- | - | - | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Payments to Stanford under license agreement for annual license fees and patent expense reimbursement
Payments to Stanford under license agreement for annual license fees and patent expense reimbursement
As co-inventor, Dr. Engleman is entitled to a share of royalties paid to Stanford under the license agreements; no royalty payments have been made to date
Consulting agreement to provide services as a Senior Clinical Advisor; terminated February 2026
Loading...